RTI Surgical Inc (NASDAQ:RTIX) has received a consensus broker rating score of 3.00 (Hold) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation.
Brokerages have set a 12 month consensus price target of $5.00 for the company and are predicting that the company will post $0.02 EPS for the current quarter, according to Zacks. Zacks has also assigned RTI Surgical an industry rank of 98 out of 255 based on the ratings given to related companies.
Get RTI Surgical alerts:Several research firms have issued reports on RTIX. BidaskClub upgraded RTI Surgical from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine upgraded RTI Surgical from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Zacks Investment Research upgraded RTI Surgical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Top Value Stocks To Buy For 2019: WSFS Financial Corporation(WSFS)
Advisors' Opinion:- [By Max Byerly]
News stories about WSFS Financial (NASDAQ:WSFS) have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. WSFS Financial earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the bank an impact score of 47.7493461022814 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
- [By Shane Hupp]
Boenning Scattergood reaffirmed their buy rating on shares of WSFS Financial (NASDAQ:WSFS) in a report published on Thursday morning.
“ECPG reported $1.33 in adjusted 2Q18 EPS, the top end of the pre-announced range (7/16). There were moving pieces, including an $18M valuation reversal, $7M of derivative MTM loss Cabot transaction hedges, and a discretionary marketing/mailing initiative (undisclosed amount). Thus, a lot of noise, but the underlying trends continue to move in the right direction, and ECPG continues to execute well. With its locked- in flow arrangements and leading positions in the US/UK markets where supply continues to increase, the company should be well positioned to continue to grow earnings. We continue to like the story and recommend investors take advantage of the fact that the stock is down ~20% since 3/31 as the fundamentals remain on track.”,” the firm’s analyst wrote.
- [By Stephan Byrd]
TRADEMARK VIOLATION NOTICE: “WSFS Financial (WSFS) to Release Quarterly Earnings on Monday” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3364455/wsfs-financial-wsfs-to-release-quarterly-earnings-on-monday.html.
- [By Joseph Griffin]
American International Group Inc. cut its position in shares of WSFS Financial Co. (NASDAQ:WSFS) by 5.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,322 shares of the bank’s stock after selling 1,039 shares during the period. American International Group Inc. owned approximately 0.06% of WSFS Financial worth $926,000 at the end of the most recent quarter.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on WSFS Financial (WSFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on WSFS Financial (WSFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Value Stocks To Buy For 2019: Ironwood Pharmaceuticals Inc.(IRWD)
Advisors' Opinion:- [By Logan Wallace]
Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Ironwood Pharmaceuticals (NASDAQ:IRWD) and GTX (NASDAQ:GTXI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Top Value Stocks To Buy For 2019: Prothena Corporation plc(PRTA)
Advisors' Opinion:- [By Chris Lange]
Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.
- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.43 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.
- [By Jon C. Ogg]
Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease treatment fails in a drug study. Now it looks as if Prothena Corporation plc (NASDAQ: PRTA) is on the verge of implosion based upon how its stock price reacted.
- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.585 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.
- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) shares dropped 68 percent to $11.79 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.
- [By Chris Lange]
Prothena Corp. PLC (NASDAQ: PRTA) shares hit a multiyear low on Monday, one not seen since 2013. This came on the heels of news that the company would be discontinuing development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis.
No comments:
Post a Comment